RuiLiMD

Oncology • Portland, OR

Physician

Join to view full profile

Dr. Li is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Li's full profile

Already have an account?

Office
4805 Ne Glisan St
Suite 6n40
Portland, OR 97213
Phone+1 503-215-5696

Education & Training

Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2010 - 2013
Mercy Hospital (St Louis)Residency, Internal Medicine, 2007 - 2010
Xian Medicine UniversityClass of 1996

Certifications & Licensure

OR State Medical License 2012 - 2025
NY State Medical License 2007 - 2018
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Phase I Study of Safety and Immunogenicity of ADU-623 Start of enrollment: 2014 Jan 08
Completed
Phase 1
Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma Start of enrollment: 2014 May 08
Completed
Phase 1
α-TEA in Advanced Cancer Start of enrollment: 2014 Aug 04
Completed
Phase 1
Pilot Study of DRibble Vaccine for Prostate Cancer Patients Start of enrollment: 2014 Oct 24
Completed
Phase 1
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients Start of enrollment: 2019 Apr 03
Active, not recruiting
Phase 2
Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer Start of enrollment: 2021 Sep 10
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

2 citations
Regorafenib in Patients With Solid Tumors WithAlterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Vaibhav Sahai, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Vijay Suhag
JCO Precision Oncology. 2024-04-01
11 citations
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
Herbert L Duvivier, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Eugene R Ahn
Journal of Clinical Oncology. 2023-11-20
6 citations
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer WithMutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.
Apar K Ganti, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Elie G Dib
JCO Precision Oncology. 2023-06-01

Lectures

Use of Diabetes Self-Management Education and Training in Persons with Newly Diagnosed Diabetes with Private Insurance in the United States, 2011
Atlanta, GA - 6/15/2014

Press Mentions

Formaldehyde-Induced Hematopoietic Stem and Progenitor Cell Toxicity in Mouse Lung and NoseOctober 21st, 2020
Histopathological Distinction of Non-Invasive and Invasive Bladder Cancers Using Machine Learning ApproachesJuly 17th, 2020